Atlas market file · Equity · United States
BioXcel Therapeutics, Inc.BTAI
- Last close
- 0.8302
- Change
- -1.28%
- 96-bar range
- 0.737 – 1.62
- As of
- 6 Aug 2026
BioXcel Therapeutics, Inc. is a pharmaceutical preparations issuer listed as BTAI on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
BTAI
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-92.36% over the window).
Source rail: Yahoo Finance chart API (BTAI). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for BTAI. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
BTAI public profile
Pharmaceutical preparations issuer. BioXcel Therapeutics, Inc. is connected to current market context, cited company sources and its retained research file.
BioXcel Therapeutics, Inc. trades as BTAI on NASDAQ. BioXcel Therapeutics, Inc. (BTAI) has a latest verified close of 0.8302, down 1.28%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files BTAI under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for BioXcel Therapeutics, Inc. today
On July 28, 2026, BioXcel Therapeutics (BTAI) trades as a microcap equity with a market cap dwarfed by its liabilities. The company’s Q1 2026 financials reveal $206,000 in revenue against a net loss of $12.7M, operating cash burn of $11.8M, and negative stockholders’ equity of $105.5M. Despite FDA approval for its antipsychotic nasal spray Igalmi, commercial traction remains elusive, with inventory declining by $222K and R&D spend outpacing revenue by a factor of 14.
BTAI’s core business revolves around Igalmi and its AI-driven drug discovery platform, EvolverAI. However, the SEC filings paint a picture of a company struggling to convert regulatory wins into sustainable revenue. With $17.2M in cash and no capital expenditures, the firm’s liquidity hinges on its ability to issue shares or secure partnerships-a risky proposition given its current burn rate and lack of positive catalysts.
The March 2026 10-Q filing highlights significant risks: a 23.6M diluted share count, $139.6M in liabilities, and a reliance on a single product. While the company’s press release from May 15, 2026, celebrated Igalmi’s approval, the financials tell a different story. Inventory shrinkage and zero cash from operations underscore the gap between promotional narratives and operational reality.
Chart watchers have no technical levels to cling to, as BTAI’s trading volume remains thin and its price action disconnected from fundamentals. The lack of buybacks or insider purchases suggests management is more focused on survival than signaling confidence. For now, the stock is a speculative bet on future approvals or a takeover, with little downside protection.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
BTAI technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on BTAI
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep BTAI research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
BTAI FAQ
What is BioXcel Therapeutics, Inc. (BTAI)?BioXcel Therapeutics, Inc. (BTAI) has a latest verified close of 0.8302, down 1.28%, dated 6 Aug 2026. Use this page to check the price chart, company context,...
BioXcel Therapeutics, Inc. (BTAI) has a latest verified close of 0.8302, down 1.28%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for BTAI?BioXcel Therapeutics, Inc. (BTAI) has a latest verified close of 0.8302, down 1.28%, dated 6 Aug 2026. It brings the latest available chart, company context, cited...
BioXcel Therapeutics, Inc. (BTAI) has a latest verified close of 0.8302, down 1.28%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files BTAI under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the BTAI page updated?The BTAI public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The BTAI public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for BTAI?The BTAI file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:BTAI. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The BTAI file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:BTAI. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on BTAI?Yes. The workstation can open BTAI, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open BTAI, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this BTAI page investment advice?No. The BTAI page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The BTAI page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →